Ultragenyx to Sell FDA Priority Review Voucher for $210M

Ultragenyx Pharmaceutical has entered a $210M deal to sell an FDA priority review voucher tied to the recent approval of Genglycos, according to Seeking Alpha. The publisher reported that Ultragenyx stock gained as the company announced the transaction.

The reported deal concerns an FDA priority review voucher, a regulatory asset associated with the Genglycos approval. Seeking Alpha identified the sale price as $210M.

Regulatory asset sale tied to Genglycos

According to Seeking Alpha, the voucher being sold is linked to Ultragenyx’s recent Genglycos approval. The company’s agreement to sell the voucher separates the regulatory asset transaction from the approved product itself.

The announcement puts the focus on a transaction involving a voucher received in connection with an FDA approval. Seeking Alpha reported that Ultragenyx is selling that voucher under a $210M deal.

For professionals following pharmaceutical and biotech commercial activity, the event connects a recent approval with a separate corporate transaction. The reported agreement centers on the priority review voucher and its stated $210M value.

Seeking Alpha reports market response

Seeking Alpha reported that Ultragenyx stock gained following the news. The publisher’s summary described the transaction as a deal to sell an FDA priority review voucher tied to Genglycos approval.

The reported sale is not described as a product acquisition or a company merger. Instead, it involves the sale of a specific regulatory asset associated with a recent approval.

Ultragenyx’s announcement illustrates how an FDA-related voucher can become the subject of a distinct transaction after an approval milestone. Based on Seeking Alpha’s report, the key disclosed elements are the company, the voucher, its connection to Genglycos approval, and the $210M deal value.

Key reported details

• Ultragenyx Pharmaceutical is selling an FDA priority review voucher.
• Seeking Alpha reported the deal value as $210M.
• The voucher is tied to the recent approval of Genglycos.
• Seeking Alpha reported that Ultragenyx stock gained on the news.